KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Deffered Revenue: 2018-2021

Historic Non-Current Deffered Revenue for Castle Biosciences (CSTL) over the last 3 years, with Sep 2021 value amounting to $986,000.

  • Castle Biosciences' Non-Current Deffered Revenue fell 13.51% to $986,000 in Q3 2021 from the same period last year, while for Sep 2021 it was $986,000, marking a year-over-year decrease of 13.51%. This contributed to the annual value of $1.7 million for FY2020, which is 3054.55% up from last year.
  • Castle Biosciences' Non-Current Deffered Revenue amounted to $986,000 in Q3 2021, which was up 2.39% from $963,000 recorded in Q2 2021.
  • In the past 5 years, Castle Biosciences' Non-Current Deffered Revenue ranged from a high of $1.7 million in Q4 2020 and a low of $44,000 during Q4 2018.
  • Its 3-year average for Non-Current Deffered Revenue is $698,170, with a median of $952,000 in 2020.
  • As far as peak fluctuations go, Castle Biosciences' Non-Current Deffered Revenue surged by 3,054.55% in 2020, and later fell by 13.51% in 2021.
  • Quarterly analysis of 4 years shows Castle Biosciences' Non-Current Deffered Revenue stood at $44,000 in 2018, then grew by 25.00% to $55,000 in 2019, then skyrocketed by 3,054.55% to $1.7 million in 2020, then fell by 13.51% to $986,000 in 2021.
  • Its Non-Current Deffered Revenue stands at $986,000 for Q3 2021, versus $963,000 for Q2 2021 and $995,000 for Q1 2021.